PCGR yields 2000000.00% · ABBV yields 3.12%● Live data
📍 PCGR pulled ahead of the other in Year 1
Combined, PCGR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCGR + ABBV for your $10,000?
PC Group, Inc., through its subsidiaries, offers personal care products for the private label retail, medical, and therapeutic markets primarily in the United States, Canada, and Europe. Its personal care products include soaps, cleansers, toners, moisturizers, exfoliants, and facial masks, as well as over-the-counter drug products, such as acne soaps; and gel-based products, including gloves and sock products that are used for cosmetic and scar management purposes. The company's gel-based orthopedic products include digitcare products, diabetes management products, products that protect the hands and wrists, gel sheeting products for various applications, and pressure, friction, and shear force absorption products, as well as products for the treatment of common orthopedic and footcare conditions; and gel-based prosthetic products for the treatment of common orthopedic and footcare conditions. PC Group sells its personal care products through account representatives to health and beauty companies, specialty retailers, cosmetics companies, direct marketing companies, amenities companies, health clubs and spas, and catalog companies; and medical products through national and regional account managers, field sales representatives, and inside sales representatives, as well as through medical distributors. The company was formerly known as Langer, Inc. and changed its name to PC Group, Inc. in July 2009 as a result of business focus shift to personal care products business. PC Group, Inc. was founded in 1971 and is headquartered in New York, New York.
Full PCGR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.